Related references
Note: Only part of the references are listed.Withanone and Withaferin-A are predicted to interact with transmembrane protease serine 2 (TMPRSS2) and block entry of SARS-CoV-2 into cells
Vipul Kumar et al.
JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS (2022)
Induction of Senescence in Cancer Cells by a Novel Combination of Cucurbitacin B and Withanone: Molecular Mechanism and Therapeutic Potential
Sukant Garg et al.
JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES (2020)
Combination of Withaferin-A and CAPE Provides Superior Anticancer Potency: Bioinformatics and Experimental Evidence to Their Molecular Targets and Mechanism of Action
Anissa Nofita Sari et al.
CANCERS (2020)
Bioinformatics and Molecular Insights to Anti-Metastasis Activity of Triethylene Glycol Derivatives
Vidhi Malik et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Withanolide-Type Steroids from Withania aristata as Potential Anti-Leukemic Agents
Laila M. Moujir et al.
MOLECULES (2020)
Molecular Insights Into Withaferin-A-Induced Senescence: Bioinformatics and Experimental Evidence to the Role of NFκB and CARF
Priyanshu Bhargava et al.
JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES (2019)
Wild type p53 function in p53Y220C mutant harboring cells by treatment with Ashwagandha derived anticancer withanolides: bioinformatics and experimental evidence
Durai Sundar et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
Newer-Generation EGFR Inhibitors in Lung Cancer: How Are They Best Used?
Tri Le et al.
CANCERS (2019)
EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer
Wenfeng Fang et al.
BMC CANCER (2019)
Intrinsic Resistance to EGFR-Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Differences and Similarities with Acquired Resistance
Eric Santoni-Rugiu et al.
CANCERS (2019)
CAPE-pNO2 Inhibited the Growth and Metastasis of Triple-Negative Breast Cancer via the EGFR/STAT3/Akt/E-Cadherin Signaling Pathway
Qin Huang et al.
FRONTIERS IN ONCOLOGY (2019)
TAS6417/CLN-081 Is a Pan-Mutation-Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant EGFR Mutations
Hibiki Udagawa et al.
MOLECULAR CANCER RESEARCH (2019)
Withania Somnifera (Ashwagandha) and Withaferin A: Potential in Integrative Oncology
Rinku Dutta et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
2, 3-Dihydro-3β-methoxy Withaferin-A Lacks Anti-Metastasis Potency: Bioinformatics and Experimental Evidences
Anupama Chaudhary et al.
SCIENTIFIC REPORTS (2019)
Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer
Simon Vyse et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2019)
The effects of pollen, propolis, and caffeic acid phenethyl ester on tyrosine hydroxylase activity and total RNA levels in hypertensive rats caused by nitric oxide synthase inhibition: experimental, docking and molecular dynamic studies
Ramin Ekhteiari Salmas et al.
JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS (2018)
Emerging functions of the EGFR in cancer
Sara Sigismund et al.
MOLECULAR ONCOLOGY (2018)
Caffeic acid phenethyl ester (CAPE) possesses pro-hypoxia and anti-stress activities: bioinformatics and experimental evidences
Priyanshu Bhargava et al.
CELL STRESS & CHAPERONES (2018)
Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions
Nicolas Floc'h et al.
MOLECULAR CANCER THERAPEUTICS (2018)
TAS6417, A Novel EGFR Inhibitor Targeting Exon 20 Insertion Mutations
Shinichi Hasako et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer
Jacqulyne P. Robichaux et al.
NATURE MEDICINE (2018)
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer
J. -C. Soria et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Withaferin-A kills cancer cells with and without telomerase: chemical, computational and experimental evidences
Yue Yu et al.
CELL DEATH & DISEASE (2017)
Molecular docking, QSAR and ADMET studies of withanolide analogs against breast cancer
Dharmendra K. Yadav et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2017)
A Phase II Study of Poziotinib in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Lung Adenocarcinoma Who Have Acquired Resistance to EGFR Tyrosine Kinase Inhibitors
Ji-Youn Han et al.
CANCER RESEARCH AND TREATMENT (2017)
Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways
Ping Wee et al.
CANCERS (2017)
Activation of the EGF Receptor by Ligand Binding and Oncogenic Mutations: The Rotation Model
Endang R. Purba et al.
CELLS (2017)
Glucose metabolism-targeted therapy and withaferin A are effective for epidermal growth factor receptor tyrosine kinase inhibitor-induced drug-tolerant persisters
Kei Kunimasa et al.
CANCER SCIENCE (2017)
OPLS3: A Force Field Providing Broad Coverage of Drug-like Small Molecules and Proteins
Edward Harder et al.
JOURNAL OF CHEMICAL THEORY AND COMPUTATION (2016)
PubChem Substance and Compound databases
Sunghwan Kim et al.
NUCLEIC ACIDS RESEARCH (2016)
Non-small cell lung cancer: current treatment and future advances
Cecilia Zappa et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2016)
Lung cancer: Biology and treatment options
Hassan Lemjabbar-Alaoui et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2015)
Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer
Bin-Chi Liao et al.
CURRENT OPINION IN ONCOLOGY (2015)
The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities
Samuel Genheden et al.
EXPERT OPINION ON DRUG DISCOVERY (2015)
Withanone-Rich Combination of Ashwagandha Withanolides Restricts Metastasis and Angiogenesis through hnRNP-K
Ran Gao et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Receptor Tyrosine Kinases: Legacy of the First Two Decades
Joseph Schlessinger
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2014)
AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer
Darren A. E. Cross et al.
CANCER DISCOVERY (2014)
Mechanisms of Activation of Receptor Tyrosine Kinases: Monomers or Dimers
Ichiro N. Maruyama
CELLS (2014)
Erlotinib in wild type epidermal growth factor receptor non-small cell lung cancer: A systematic review
Abdul-Rahman Jazieh et al.
ANNALS OF THORACIC MEDICINE (2013)
Withanone as an inhibitor of survivin: A potential drug candidate for cancer therapy
Varsha P. Wadegaonkar et al.
JOURNAL OF BIOTECHNOLOGY (2013)
MM/GBSA Binding Energy Prediction on the PDBbind Data Set: Successes, Failures, and Directions for Further Improvement
Paulette A. Greenidge et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2013)
Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments
G. Madhavi Sastry et al.
JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN (2013)
Could MM-GBSA be accurate enough for calculation of absolute protein/ligand binding free energies?
Chandrika Mulakala et al.
JOURNAL OF MOLECULAR GRAPHICS & MODELLING (2013)
Withaferin A inhibits matrix metalloproteinase-9 activity by suppressing the Akt signaling pathway
Dae Hyung Lee et al.
ONCOLOGY REPORTS (2013)
Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer
Hiroyuki Yasuda et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Role of Erlotinib in the Treatment of Non-Small Cell Lung Cancer Clinical Outcomes in Wild-Type Epidermal Growth Factor Receptor Patients
Bilal Piperdi et al.
DRUGS (2012)
Withanone binds to mortalin and abrogates mortalin-p53 complex: Computational and experimental evidence
Abhinav Grover et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2012)
Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models
Mi Young Cha et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship
Julian R. Molina et al.
MAYO CLINIC PROCEEDINGS (2012)
Ashwagandha Derived Withanone Targets TPX2-Aurora A Complex: Computational and Experimental Evidence to its Anticancer Activity
Abhinav Grover et al.
PLOS ONE (2012)
Differential Activities of the Two Closely Related Withanolides, Withaferin A and Withanone: Bioinformatics and Experimental Evidences
Kirti Vaishnavi et al.
PLOS ONE (2012)
AN OVERVIEW ON ASHWAGANDHA: A RASAYANA (REJUVENATOR) OF AYURVEDA
Narendra Singh et al.
AFRICAN JOURNAL OF TRADITIONAL COMPLEMENTARY AND ALTERNATIVE MEDICINES (2011)
Caffeic acid phenethyl ester (CAPE), derived from a honeybee product propolis, exhibits a diversity of anti-tumor effects in pre-clinical models of human breast cancer
Jing Wu et al.
CANCER LETTERS (2011)
Lung Cancer: Epidemiology, Etiology, and Prevention
Charles S. Dela Cruz et al.
CLINICS IN CHEST MEDICINE (2011)
Selective Killing of Cancer Cells by Ashwagandha Leaf Extract and Its Component Withanone Involves ROS Signaling
Nashi Widodo et al.
PLOS ONE (2010)
Bee products prevent VEGF-induced angiogenesis in human umbilical vein endothelial cells
Hiroshi Izuta et al.
BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE (2009)
Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors
A. F. Gazdar
ONCOGENE (2009)
Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer
Jeffrey A. Engelman et al.
CLINICAL CANCER RESEARCH (2008)
International Registries of Families at High Risk of Pancreatic Cancer
William Greenhalf et al.
PANCREATOLOGY (2008)
Erlotinib: an EGF receptor tyrosine kinase inhibitor in non-small-cell lung cancer treatment
Clorinda Schettino et al.
Expert Review of Respiratory Medicine (2008)
Regulation of MAPKs by growth factors and receptor tyrosine kinases
Menachem Katz et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2007)
Structures of lung cancer-derived EGFR mutants and inhibitor complexes: Mechanism of activation and insights into differential inhibitor sensitivity
Cai-Hong Yun et al.
CANCER CELL (2007)
Extra precision glide: Docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes
Richard A. Friesner et al.
JOURNAL OF MEDICINAL CHEMISTRY (2006)
An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor
Xuewu Zhang et al.
CELL (2006)
Gefitinib, an EGFR tyrosine kinase inhibitor, directly inhibits the function of P-glycoprotein in multidrug resistant cancer cells
T Kitazaki et al.
LUNG CANCER (2005)
Caffeic acid phenethyl ester induces apoptosis by inhibition of NFκB and activation of Fas in human breast cancer MCF-7 cells
M Watabe et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Role of caffeic acid phenethyl ester, an active component of propolis, against cisplatin-induced nephrotoxicity in rats
S Ozen et al.
JOURNAL OF APPLIED TOXICOLOGY (2004)
Share Paper
